

**TOXICOLOGICAL PROFILE FOR
LEAD**

**U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES
Public Health Service
Agency for Toxic Substances and Disease Registry**

July 1999

DISCLAIMER

The use of company or product name(s) is for identification only and does not imply endorsement by the Agency for Toxic Substances and Disease Registry.

UPDATE STATEMENT

A Toxicological Profile for Lead, Draft for Public Comment, was released in September 1997. This edition supersedes any previously released draft or final profile.

Toxicological profiles are revised and republished as necessary, but no less than once every three years. For information regarding the update status of previously released profiles, contact ATSDR at:

Agency for Toxic Substances and Disease Registry
Division of Toxicology/Toxicology Information Branch
1600 Clifton Road NE, E-29
Atlanta, Georgia 30333

FOREWORD

This toxicological profile is prepared in accordance with guidelines* developed by the Agency for Toxic Substances and Disease Registry (ATSDR) and the Environmental Protection Agency (EPA). The original guidelines were published in the *Federal Register* on April 17, 1987. Each profile will be revised and republished as necessary.

The ATSDR toxicological profile succinctly characterizes the toxicologic and adverse health effects information for the hazardous substance described therein. Each peer-reviewed profile identifies and reviews the key literature that describes a hazardous substance's toxicologic properties. Other pertinent literature is also presented, but is described in less detail than the key studies. The profile is not intended to be an exhaustive document; however, more comprehensive sources of specialty information are referenced.


The focus of the profiles is on health and toxicologic information; therefore, each toxicological profile begins with a public health statement that describes, in nontechnical language, a substance's relevant toxicological properties. Following the public health statement is information concerning levels of significant human exposure and, where known, significant health effects. The adequacy of information to determine a substance's health effects is described in a health effects summary. Data needs that are of significance to protection of public health are identified by ATSDR and EPA.

Each profile includes the following:

- (A) The examination, summary, and interpretation of available toxicologic information and epidemiologic evaluations on a hazardous substance to ascertain the levels of significant human exposure for the substance and the associated acute, subacute, and chronic health effects;
- (B) A determination of whether adequate information on the health effects of each substance is available or in the process of development to determine levels of exposure that present a significant risk to human health of acute, subacute, and chronic health effects; and
- (C) Where appropriate, identification of toxicologic testing needed to identify the types or levels of exposure that may present significant risk of adverse health effects in humans.

The principal audiences for the toxicological profiles are health professionals at the Federal, State, and local levels; interested private sector organizations and groups; and members of the public.

This profile reflects ATSDR's assessment of all relevant toxicologic testing and information that has been peer-reviewed. Staff of the Centers for Disease Control and Prevention and other Federal scientists have also reviewed the profile. In addition, this profile has been peer-reviewed by a nongovernmental panel and was made available for public review. Final responsibility for the contents and views expressed in this toxicological profile resides with ATSDR.



Jeffrey P. Koplan, M.D., M.P.H.

Administrator

Agency for Toxic Substances and
Disease Registry

***Legislative Background**

The toxicological profiles are developed in response to the Superfund Amendments and Reauthorization Act (SARA) of 1986 (Public Law 99-499) which amended the Comprehensive Environmental Response, Compensation, and Liability Act of 1980 (CERCLA or Superfund). This public law directed ATSDR to prepare toxicological profiles for hazardous substances most commonly found at facilities on the CERCLA National Priorities List and that pose the most significant potential threat to human health, as determined by ATSDR and the EPA. The availability of the revised priority list of 275 hazardous substances was announced in the *Federal Register* on November 17, 1997 (62 FR 61332). For prior versions of the list of substances, see *Federal Register* notices dated April 29, 1996 (61 FR 18744); April 17, 1987 (52 FR 12866); October 20, 1988 (53 FR 41280); October 26, 1989 (54 FR 43619); October 17, 1990 (55 FR 42067); October 17, 1991 (56 FR 52166); October 28, 1992 (57 FR 48801); and February 28, 1994 (59 FR 9486). Section 104(i)(3) of CERCLA, as amended, directs the Administrator of ATSDR to prepare a toxicological profile for each substance on the list.

QUICK REFERENCE FOR HEALTH CARE PROVIDERS

Toxicological Profiles are a unique compilation of toxicological information on a given hazardous substance. Each profile reflects a comprehensive and extensive evaluation, summary, and interpretation of available toxicologic and epidemiologic information on a substance. Health care providers treating patients potentially exposed to hazardous substances will find the following information helpful for fast answers to often-asked questions.

Primary Chapters/Sections of Interest

Chapter 1: Public Health Statement: The Public Health Statement can be a useful tool for educating patients about possible exposure to a hazardous substance. It explains a substance's relevant toxicologic properties in a nontechnical, question-and-answer format, and it includes a review of the general health effects observed following exposure.

Chapter 2: Health Effects: Specific health effects of a given hazardous compound are reported by *route of exposure*, by *type of health effect* (death, systemic, immunologic, reproductive), and by *length of exposure* (acute, intermediate, and chronic). In addition, both human and animal studies are reported in this section.

NOTE: Not all health effects reported in this section are necessarily observed in the clinical setting. Please refer to the Public Health Statement to identify general health effects observed following exposure.

Pediatrics: Four new sections have been added to each Toxicological Profile to address child health issues:

Section 1.6	How Can (Chemical X) Affect Children?
Section 1.7	How Can Families Reduce the Risk of Exposure to (Chemical X)?
Section 2.6	Children's Susceptibility
Section 5.6	Exposures of Children

Other Sections of Interest:

Section 2.7	Biomarkers of Exposure and Effect
Section 2.10	Methods for Reducing Toxic Effects

ATSDR Information Center

Phone: 1-888-42-ATSDR (1-888-422-8737)
or 404-639-6357

Fax: 404-639-6359

E-mail: atsdric@cdc.gov

Internet: <http://www.atsdr.cdc.gov>

The following additional material can be ordered through the ATSDR Information Center:

Case Studies in Environmental Medicine: Taking an Exposure History—The importance of taking an exposure history and how to conduct one are described, and an example of a thorough exposure history is provided. Other case studies of interest include *Reproductive and Developmental Hazards*; *Skin Lesions and Environmental Exposures*; *Cholinesterase-Inhibiting Pesticide Toxicity*; and numerous chemical-specific case studies.

Managing Hazardous Materials Incidents is a three-volume set of recommendations for on-scene (prehospital) and hospital medical management of patients exposed during a hazardous materials incident. Volumes I and II are planning guides to assist first responders and hospital emergency department personnel in planning for incidents that involve hazardous materials. Volume III—*Medical Management Guidelines for Acute Chemical Exposures*—is a guide for health care professionals treating patients exposed to hazardous materials.

Fact Sheets (ToxFAQs) provide answers to frequently asked questions about toxic substances.

Other Agencies and Organizations

The National Center for Environmental Health (NCEH) focuses on preventing or controlling disease, injury, and disability related to the interactions between people and their environment outside the workplace. *Contact:* NCEH, Mailstop F-29, 4770 Buford Highway, NE, Atlanta, GA 30341-3724 • Phone: 770-488-7000 • FAX: 770-488-7015.

The National Institute for Occupational Safety and Health (NIOSH) conducts research on occupational diseases and injuries, responds to requests for assistance by investigating problems of health and safety in the workplace, recommends standards to the Occupational Safety and Health Administration (OSHA) and the Mine Safety and Health Administration (MSHA), and trains professionals in occupational safety and health. *Contact:* NIOSH, 200 Independence Avenue, SW, Washington, DC 20201 • Phone: 800-356-4674 or NIOSH Technical Information Branch, Robert A. Taft Laboratory, Mailstop C-19, 4676 Columbia Parkway, Cincinnati, OH 45226-1998 • Phone: 800-35-NIOSH.

The National Institute of Environmental Health Sciences (NIEHS) is the principal federal agency for biomedical research on the effects of chemical, physical, and biologic environmental agents on human health and well-being. *Contact:* NIEHS, PO Box 12233, 104 T.W. Alexander Drive, Research Triangle Park, NC 27709 • Phone: 919-541-3212.

Referrals

The Association of Occupational and Environmental Clinics (AOEC) has developed a network of clinics in the United States to provide expertise in occupational and environmental issues. *Contact:* AOEC, 1010 Vermont Avenue, NW, #513, Washington, DC 20005 • Phone: 202-347-4976 • FAX: 202-347-4950 • e-mail: aoec@dgs.dgsys.com • AOEC Clinic Director: <http://occ-env-med.mc.duke.edu/oem/aoec.htm>.

The American College of Occupational and Environmental Medicine (ACOEM) is an association of physicians and other health care providers specializing in the field of occupational and environmental medicine. *Contact:* ACOEM, 55 West Seegers Road, Arlington Heights, IL 60005 • Phone: 847-228-6850 • FAX: 847-228-1856.

CONTRIBUTORS

CHEMICAL MANAGER(S)/AUTHORS(S):

Henry Abadin, M.S.P.H.
ATSDR, Division of Toxicology, Atlanta, GA

Fernando Lladós, Ph.D.
Syracuse Research Corporation, Syracuse, NY

THE PROFILE HAS UNDERGONE THE FOLLOWING ATSDR INTERNAL REVIEWS:

1. Health Effects Review. The Health Effects Review Committee examines the health effects chapter of each profile for consistency and accuracy in interpreting health effects and classifying end points.
2. Minimal Risk Level Review. The Minimal Risk Level Workgroup considers issues relevant to substance-specific minimal risk levels (MRLs), reviews the health effects database of each profile, and makes recommendations for derivation of MRLs.
3. Data Needs Review. The Research Implementation Branch reviews data needs sections to assure consistency across profiles and adherence to instructions in the Guidance.

PEER REVIEW

A peer review panel was assembled for lead. The panel consisted of the following members:

1. Dr. Deborah Cory-Slechta, Professor of Environmental Medicine, Neurobiology and Anatomy, Department of Environmental Medicine, University of Rochester, Rochester, New York;
2. Dr. Joseph P. Gould, Research Scientist, School of Civil Engineering, Georgia Institute of Technology, Atlanta, Georgia;
3. Dr. Shane Que Hee, Professor, Department of Environmental Health Sciences, UCLA School of Public Health, Los Angeles, California; and
4. Dr. Marty Kanarek, Professor, Department of Preventive Medicine, University of Wisconsin, Madison, Wisconsin.

These experts collectively have knowledge of lead's physical and chemical properties, toxicokinetics, key health end points, mechanisms of action, human and animal exposure, and quantification of risk to humans. All reviewers were selected in conformity with the conditions for peer review specified in Section 104(i)(13) of the Comprehensive Environmental Response, Compensation, and Liability Act, as amended.

Scientists from the Agency for Toxic Substances and Disease Registry (ATSDR) have reviewed the peer reviewers' comments and determined which comments will be included in the profile. A listing of the peer reviewers' comments not incorporated in the profile, with a brief explanation of the rationale for their exclusion, exists as part of the administrative record for this compound. A list of databases reviewed and a list of unpublished documents cited are also included in the administrative record.

The citation of the peer review panel should not be understood to imply its approval of the profile's final content. The responsibility for the content of this profile lies with the ATSDR.

CONTENTS

FOREWORD	v
QUICK REFERENCE FOR HEALTH CARE PROVIDERS	vii
CONTRIBUTORS	ix
PEER REVIEW	xi
LIST OF FIGURES	xviii
LIST OF TABLES	xx
1. PUBLIC HEALTH STATEMENT	1
1.1 WHAT IS LEAD?	1
1.2 WHAT HAPPENS TO LEAD WHEN IT ENTERS THE ENVIRONMENT?	2
1.3 HOW MIGHT I BE EXPOSED TO LEAD?	4
1.4 HOW CAN LEAD ENTER AND LEAVE MY BODY?	6
1.5 HOW CAN LEAD AFFECT MY HEALTH?	8
1.6 HOW CAN LEAD AFFECT CHILDREN?	9
1.7 HOW CAN FAMILIES REDUCE THE RISK OF EXPOSURE TO LEAD?	10
1.8 IS THERE A MEDICAL TEST TO DETERMINE WHETHER I HAVE BEEN EXPOSED TO LEAD?	13
1.9 WHAT RECOMMENDATIONS HAS THE FEDERAL GOVERNMENT MADE TO PROTECT HUMAN HEALTH?	13
1.10 WHERE CAN I GET MORE INFORMATION?	16
2. HEALTH EFFECTS	19
2.1 INTRODUCTION	19
2.2 DISCUSSION OF HEALTH EFFECTS BY ROUTE OF EXPOSURE	19
2.2.1 Effects in Humans Based on Blood Lead (PbB) Levels	22
2.2.1.1 Death	22
2.2.1.2 Systemic Effects	35
2.2.1.3 Immunological Effects	65
2.2.1.4 Neurological Effects	68
2.2.1.5 Reproductive Effects	93
2.2.1.6 Developmental Effects	98
2.2.1.7 Genotoxic Effects	113
2.2.1.8 Cancer	114
2.2.2 Inhalation Exposure	116
2.2.2.1 Death	116
2.2.2.2 Systemic Effects	116
2.2.2.3 Immunological Effects	122
2.2.2.4 Neurological Effects	123
2.2.2.5 Developmental Effects	123
2.2.2.6 Reproductive Effects	124
2.2.2.7 Genotoxic Effects	124
2.2.2.8 Cancer	124
2.2.3 Oral Exposure	124

2.2.3.1	Death	124
2.2.3.2	Systemic Effects	126
2.2.3.3	Immunological Effects	172
2.2.3.4	Neurological Effects	174
2.2.3.5	Reproductive Effects	184
2.2.3.7	Genotoxic Effects	193
2.2.3.8	Cancer	194
2.2.4	Dermal Exposure	195
2.2.4.1	Death	195
2.2.4.2	Systemic Effects	195
2.2.4.3	Immunological Effects	195
2.2.4.4	Neurological Effects	195
2.2.4.5	Reproductive Effects	195
2.2.4.6	Developmental Effects	195
2.2.4.7	Genotoxic Effects	195
2.2.4.8	Cancer	195
2.3	TOXICOKINETICS	196
2.3.1	Absorption	197
2.3.1.1	Inhalation Exposure	197
2.3.1.2	Oral Exposure	199
2.3.1.3	Dermal Exposure	203
2.3.2	Distribution	205
2.3.2.1	Blood and Other Soft Tissues	205
2.3.2.2	Bone	211
2.3.3	Metabolism	212
2.3.4	Excretion	213
2.3.5	Physiologically Based Pharmacokinetic (PBPK)/Pharmacodynamic (PD) Models	215
2.3.5.1	Summary of Physiologically Based and Classical Pharmacokinetic Models.	219
2.3.5.2	Lead PBPK Model Comparison and Discussion	223
2.4	MECHANISMS OF ACTION	239
2.4.1	Pharmacokinetic Mechanisms	239
2.4.2	Mechanisms of Toxicity	245
2.4.3	Animal-to-Human Extrapolations	257
2.5	RELEVANCE TO PUBLIC HEALTH	257
2.6	CHILDREN'S SUSCEPTIBILITY	291
2.7	BIOMARKERS OF EXPOSURE AND EFFECT	295
2.7.1	Biomarkers Used to Identify or Quantify Exposure to Lead	296
2.7.1.1	Lead in Soft Tissues	296
2.7.1.2	Lead in Bones and Teeth	301
2.7.2	Biomarkers Used to Characterize Effects Caused by Lead	303
2.8	INTERACTIONS WITH OTHER CHEMICALS	307
2.9	POPULATIONS THAT ARE UNUSUALLY SUSCEPTIBLE	315

2.10	METHODS FOR REDUCING TOXIC EFFECTS	319
2.10.1	Reducing Peak Absorption Following Exposure	320
2.10.2	Reducing Body Burden	321
2.10.3	Interfering with the Mechanism of Action for Toxic Effects	322
2.11	ADEQUACY OF THE DATABASE	323
2.11.1	Existing Information on Health Effects of Lead	323
2.11.2	Identification of Data Needs	323
2.11.3	Ongoing Studies	342
3.	CHEMICAL AND PHYSICAL INFORMATION	357
3.1	CHEMICAL IDENTITY	357
3.2	PHYSICAL AND CHEMICAL PROPERTIES	357
4.	PRODUCTION, IMPORT, USE, AND DISPOSAL	367
4.1	PRODUCTION	367
4.2	IMPORT/EXPORT	368
4.3	USE	371
4.4	DISPOSAL	374
5.	POTENTIAL FOR HUMAN EXPOSURE	377
5.1	OVERVIEW	377
5.2	RELEASES TO THE ENVIRONMENT	378
5.2.1	Air	382
5.2.2	Water	385
5.2.3	Soil	385
5.2.4	Paint	386
5.3	ENVIRONMENTAL FATE	388
5.3.1	Transport and Partitioning	388
5.3.2	Transformation and Degradation	393
5.3.2.1	Air	393
5.3.2.2	Water	394
5.3.2.3	Sediment and Soil	394
5.4	LEVELS MONITORED OR ESTIMATED IN THE ENVIRONMENT	395
5.4.1	Air	396
5.4.2	Water	397
5.4.3	Sediment and Soil	399
5.4.4	Paint	402
5.4.5	Other Sources	403
5.5	GENERAL POPULATION AND OCCUPATIONAL EXPOSURE	407
5.6	EXPOSURES OF CHILDREN	414
5.7	POPULATIONS WITH POTENTIALLY HIGH EXPOSURES	423
5.8	ADEQUACY OF THE DATABASE	424
5.8.1	Identification of Data Needs	424
5.8.2	Ongoing Studies	427
6.	ANALYTICAL METHODS	431
6.1	BIOLOGICAL SAMPLES	431
6.2	ENVIRONMENTAL SAMPLES	439

6.3	ADEQUACY OF THE DATABASE	446
6.3.1	Identification of Data Needs	447
6.3.2	Ongoing Studies	448
7.	REGULATIONS AND ADVISORIES	449
8.	REFERENCES	473
9.	GLOSSARY	581
APPENDICES		
A.	ATSDR MINIMAL RISK LEVELS AND WORKSHEETS	A-1
B.	USER'S GUIDE	B-1
C.	ACRONYMS, ABBREVIATIONS, AND SYMBOLS	C-1
D.	A FRAMEWORK TO GUIDE PUBLIC HEALTH ASSESSMENT DECISIONS AT LEAD SITES	D-1

LIST OF FIGURES

2-1	Levels of Significant Exposure to Lead—Inhalation	120
2-2	Levels of Significant Exposure to Lead—Oral	154
2-3	Curvilinear Relationship of Human Serum Lead to Blood Lead	207
2-4	Conceptual Representation of a Physiologically Based Pharmacokinetic (PBPK) Model for a Hypothetical Chemical Substance	217
2-5	Lead Metabolism Model	220
2-6	A Compartmental Model for Lead Biokinetics with Multiple Pool for Blood Lead	221
2-7	Compartments and Pathways of Lead Exchange in the O’Flaherty Model	225
2-8	Structure of the IEUBK Model for Lead in Children	230
2-9	Compartments and Pathways of Lead Exchange in the Leggett Model	235
2-10	Effects of Lead on Heme Biosynthesis	247
2-11	Multiorgan Impact of Reduction of Heme Body Pool by Lead	250
2-12	Dose-Response Curve for Erythrocyte Protoporphyrin (EP) as a Function of Blood Level in Subpopulations	305
2-13	Existing Information on Health Effects of Lead	324
5-1	Frequency of NPL Sites with Lead Contamination	379

LIST OF TABLES

2-1	Health Effects Associated with Exposure to Lead and Internal Lead Doses in Humans	23
2-2	Levels of Significant Exposure to Lead—Inhalation	118
2-3	Oral LD _{LO} Values for Lead Compounds	125
2-4	Levels of Significant Exposure to Lead—Oral	127
2-5	Relative Bioavailability of Lead in Various Samples of Soil from Hazardous Waste Sites as Assessed in Immature Swine	202
2-6	Kinetic Constants and Model Parameters in the O’Flaherty Model	227
2-7	Residence Times in the Biokinetic Module of the IEUBK Model	232
2-8	Kinetic Constants and Model Parameters in the Leggett Model	237
2-9	Summary of Blood Slope Factors from Various Environmental Media	259
2-10	Genotoxicity of Lead <i>In Vivo</i>	286
2-11	Genotoxicity of Lead <i>In Vitro</i>	287
2-12	Effects of Nutritional Factors on Lead Uptake in Animals	310
2-13	Ongoing Studies on Lead	343
3-1	Chemical Identity of Lead and Compounds	358
3-2	Physical and Chemical Properties of Lead and Compounds	362
4-1	Facilities That Manufacture or Process Lead	369
4-2	U.S. Lead Production January 1990 through 1997	370
5-1	Releases to the Environment from Facilities That Manufacture or Process Lead	380
5-2	National Lead Emissions Estimates, 1986–1995	383
5-3	Daily Average Intake of Lead	410
5-4	Ongoing Studies on Lead	428

6-1	Analytical Methods for Determining Lead in Biological Samples	433
6-2	Analytical Methods for Determining Lead in Environmental Samples	440
7-1	Regulations and Guidelines Applicable to Lead	457